MGC Diagnostics Corporation Announces Worldwide Exclusive Distribution Partnership with Restech Respiratory Technology

    MGC Diagnostics Corporation Announces Worldwide Exclusive Distribution
               Partnership with Restech Respiratory Technology

PR Newswire

SAINT PAUL, Minn., March 19, 2013

SAINT PAUL, Minn., March 19, 2013 /PRNewswire/ --MGC Diagnostics Corporation
(NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology
leader, today announced that it has entered into a worldwide distribution
agreement with Restech Respiratory Technology (Restech Srl), a privately held
company spun-off from the Politecnico di Milano, Italy, to market and
distribute the Resmon Pro, Forced Oscillation Technique (FOT) device.
Manufactured by Restech Srl, the Resmon Pro aids in the diagnosis and
treatment of respiratory disease. Typically, the diagnosis of common
respiratory diseases such as asthma and chronic obstructive pulmonary disease
(COPD) involve complex measurements and maximum patient effort. Restech
developed patented technology to determine the breath-by-breath presence and
severity of expiratory flow limitation (EFL) during quiet breathing. Using the
Resmon Pro, a physician can detect the presence, severity and reversibility of
EFL, and evaluate the degree of airflow obstruction and shortness-of-breath
experienced by the patient.


Gregg O. Lehman, Ph.D., Chief Executive Officer and President of MGC
Diagnostics, commented "Our agreement with Restech is an example of how MGC
Diagnostics will execute strategic partnerships with emerging technology
providers, both within the university sciences and entrepreneurial start-up
sectors. Leveraging MGC Diagnostics global sales, marketing, and support
network provides emerging technology companies best-in-class access to
cardiorespiratory healthcare professionals and their patients throughout the

About Restech Respiratory Technology

Restech SRL is a spinoff company of Politecnico di Milano derived from a
Bioengineering Department research team of the Biomedical Technology
Laboratory (TBMLab). Their primary focus is in the development of innovative
products and services for the diagnosis, monitoring and management of patients
affected by respiratory diseases.

About MGC Diagnostics

MGC Diagnostics Corporation, (formerly Angeion Corporation) through its
subsidiary Medical Graphics Corporation, is a global medical technology
company dedicated to cardiorespiratory health solutions. MGC Diagnostics
develops, manufactures and markets non-invasive diagnostic systems. This
portfolio of products provides solutions for disease detection, integrated
care, and wellness across the spectrum of cardiorespiratory healthcare. The
Company's products are sold internationally through distributors and in the
United States through a direct sales force targeting heart and lung
specialists located in hospitals, university-based medical centers, medical
clinics, physicians' offices, pharmaceutical companies, medical device
manufacturers, and clinical research organizations (CROs). For more
information about MGC Diagnostics, visit

Cautionary Statement Regarding Forward Looking Statements

From time to time, in reports filed with the Securities and Exchange
Commission, in press releases, and in other communications to shareholders or
the investing public, MGC Diagnostics Corporation may make forward−looking
statements concerning possible or anticipated future financial performance,
business activities or plans that include the words "believes," "expects,"
"anticipates," "intends" or similar expressions. For these forward−looking
statements, the Company claims the protection of the safe harbor for
forward−looking statements contained in federal securities laws. These
forward−looking statements are subject to a number of factors, risks and
uncertainties, including those disclosed in our periodic filings with the SEC,
that could cause actual performance, activities or plans after the date the
statements are made to differ significantly from those indicated in the
forward−looking statements. For a list of these factors¸ see the sections
entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking
Statements," in the Company's Form 10-K for the year ended October 31, 2012,
and any updates in subsequent filings on Form 10-Q or Form 8-K under the
Securities Exchange Act of 1934.

Contact: Gregg O. Lehman, Ph.D.  Joe Dorame, Robert Blum, Joe Diaz
         MGC Diagnostics Corporation         Lytham Partners, LLC
         Chief Executive Officer             (602) 889-9700
         (651) 484-4874     

SOURCE MGC Diagnostics Corporation
Press spacebar to pause and continue. Press esc to stop.